Navigation Links
Angioslide Announces First Successful Below-The-Knee Procedures in the US

CAESAREA, Israel, July 11, 2012 /PRNewswire/ --

Angioslide Ltd., a provider of Embolic Capture Angioplasty solutions, today announced the successful deployment of a 3X100mm PROTEUS device for treating Peripheral Artery Disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, IN. Accommodating a 0.014" guide-wire, the new device allows physician to perform a PTA revascularization in BTK vessels while capturing and removing embolic particles.

"With PROTEUS having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures," said Dr. Prakash Makam of Community Hospital (Munster, IN). "It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischemia (CLI) patients."

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention.  Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, PROTEUS removes the captured material from the body.

"We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter," said Lihu Avitov, CEO, Angioslide. "The Current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the US, we will introduce our product to a wider number of centers."  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic suction mechanism. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic removal solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado. For more information visit our website at


Shira Doron
Marketing Director
Mobile: +972-54-9011134

SOURCE Angioslide Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
2. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
3. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
4. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
5. Genova Diagnostics, Inc. Announces the Acquisition of Metametrix, Inc.
6. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
7. Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
8. Elsevier Announces New Editor-In-Chief for Neurobiology of Learning and Memory
9. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Mesa Labs Announces New Logo
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... The McHenry ... a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. ... v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... in both surgical and non-surgical treatments, announced the expansion of his private practice ... Surgery. , Highly trained and nationally recognized for his natural approach, Dr. ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
Breaking Medicine News(10 mins):